Michael J. Dickinson

St Andrew's Place
East Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Journal: British journal of haematology

Published: July 15, 2026

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Journal: Blood advances

Published: June 29, 2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Journal: British journal of haematology

Published: June 20, 2026

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

Journal: Blood

Published: March 19, 2026

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: Blood advances

Published: February 17, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.

Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 07, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood

Published: November 04, 2025

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries.

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries.

Journal: Blood

Published: July 21, 2025

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.

Journal: British journal of haematology

Published: July 16, 2025

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 18, 2025

Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era.

Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era.

Journal: British journal of haematology

Published: May 04, 2025

Showing 1-12 of 32

Last Updated: 09/26/2026